A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular ...

Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.

Macular degeneration is a condition that affects the retina, which is neural tissue that lines the back of the eye, like wallpaper in a room. There is an important area ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

For more information on Age-Related Macular Degeneration go to the NHS website. If you've had a diagnosis, in addition to ...

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...

The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.